Related Experiment Video
Updated: Oct 17, 2025
08:34
Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
Published on: September 25, 2017
24.8K
Pharmacotherapy for hypertension-induced left ventricular hypertrophy
Leire Leache1, Marta Gutiérrez-Valencia1, Rosa M Finizola2
1Unit of Innovation and Organization, Navarre Health Service, Pamplona, Spain.
The Cochrane Database of Systematic Reviews
|October 10, 2021
Summary
We are uncertain about the effects of additional antihypertensive drug therapy on morbidity and mortality in patients with hypertension-induced left ventricular hypertrophy (LVH). While serious adverse events were similar, more patients withdrew due to adverse events in the treatment group.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Hypertension is a leading risk factor for cardiovascular disease and premature death.
- Left ventricular hypertrophy (LVH) is a common cardiac remodeling effect of hypertension, affecting over 30% of patients.
- LVH severity correlates with increased cardiovascular disease and mortality risk.
Purpose of the Study:
- To assess the impact of antihypertensive pharmacotherapy versus placebo on morbidity and mortality in adults with hypertension-induced LVH.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs) with at least 12 months follow-up.
- Inclusion criteria: adults with hypertension-induced LVH, comparing antihypertensive therapy to placebo or no treatment.
- Primary outcomes: all-cause mortality, cardiovascular events, serious adverse events.
Main Results:
- Three multicenter RCTs with 930 participants were included, with a mean follow-up of 3.8 years.
- Very low-certainty evidence indicates no significant difference in mortality, cardiovascular events, or heart failure hospitalizations between groups.
- While serious adverse events were similar, withdrawals due to adverse events were significantly higher in the antihypertensive group.
Conclusions:
- Uncertainty remains regarding the effects of additional antihypertensive therapy on morbidity and mortality in patients with hypertension-induced LVH.
- Additional antihypertensive therapy may increase withdrawals due to adverse events.
- High-quality trials are needed to clarify the benefits and risks of antihypertensives in this population.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
574
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
574
01:30Heart Failure V: Medical Management
52
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
52
01:29Cardiomyopathy V: Interprofessional Care
66
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
66
01:22Heart Failure Drugs: β-Blockers
487
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
487
01:22Heart Failure Drugs: Diuretics
532
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
532
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
284
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
284